Hepatitis Screening and Vaccination

by Posted on
Hepatitis Screening Test

Liver inflammation is a condition that causes inflammation of the liver due to viral infections, accumulation of toxins, and other noninfectious substances. It can lead to a range of health issues, some of which may be life-threatening. The virus is classified into five different strains or types, referred to as A, B, C, D, and E. Although the target organ of all strains is the liver, the key differences among them include severity of infection, modes of transmission, geographical distribution, and prevention methods.

The most common symptoms associated with liver infection are nausea, fatigue, anorexia, jaundice, abdominal pain, and joint pain. Although the symptoms may be mild, prolonged infection can lead to fatal consequences. For instance, each type of liver disease can cause FHF (fulminant hepatic failure), which significantly weakens liver efficiency.

Screening

Viral infection screening involves a diagnostic blood test for antibodies and antigens to determine whether the individual is suffering from a viral infection. When a virus or some foreign particle enters the human body, the body starts producing antibodies as a part of its immune response. Therefore, the blood sample of an individual infected with a virus will contain antibodies specific to the type of viral infection.

For diagnosis, a healthcare professional will examine patient’s blood for all strains of hepatitis virus. Diagnosis of Hepatitis A Virus is linked to the detection of HAV-specific immunoglobulin G (IgM) antibodies in the blood sample. To diagnose HBV infection, the presence of the surface antigen HBsAg in the blood should be confirmed. For HCV diagnosis, the confirmation of anti-HCV antibodies in the blood is required. To diagnose HDV infection, levels of anti-HDV immunoglobulin M (IgM) and immunoglobulin G (IgG) should be measured. For confirming the HEV infection, the presence of virus-specific IgM antibodies is tested.

Protect Against by Vaccine

Vaccination

Hepatitis A: The vaccination shot is routine for infants aged between 1 and 2 years. However, un-vaccinated juveniles, teenagers, and adults should also have this shot. Two shots are administered for six months.

Hepatitis B: The vaccination for Hepatitis B is mandatory and the first shot is administered at the time of birth. The second dose is given after six months. An unvaccinated person should also have the shot, especially if he or she is traveling to regions where the risk of getting infected is high.

Hepatitis C: In spite of millions of new cases detected every year globally, no vaccine has been developed for HCV so far. However, researchers are conducting trials to design a vaccine for the same.

Hepatitis D: The vaccine developed for HBV infection is equally effective for HBV and HDV. However, the vaccine will not work if a patient infected with HDV is already suffering from chronic HBV infection.

Hepatitis E: The vaccination for Hepatitis E Virus is not approved in all the regions.

Published by Genes2Me

Established in 2016, Genes2Me is a leading molecular diagnostics company committed to transforming healthcare through innovative, high-quality in vitro diagnostic (IVD) solutions. Built on a strong foundation of scientific excellence and precision engineering, Genes2Me develops and manufactures advanced diagnostic technologies that enable accurate, reliable, and timely clinical decision-making across diverse healthcare settings worldwide. With a comprehensive and rapidly expanding portfolio, Genes2Me offers cutting-edge solutions across molecular diagnostics, including Next Generation Sequencing (NGS) clinical assays, point-of-care (POC) testing platforms, RT-PCR kits and instruments, as well as nucleic acid extraction kits and automation systems. Designed to meet the evolving needs of modern laboratories and clinicians, our products combine performance, scalability, and operational efficiency. A vast majority of Genes2Me products are CE-IVD marked, reflecting our commitment to global quality benchmarks, regulatory compliance, and uncompromising product standards. At the heart of our innovation are proprietary platforms such as OnePCR and Rapi-Q, developed to deliver rapid, multiplex, and highly sensitive molecular detection with streamlined workflows and minimal turnaround time. OnePCR integrates automated nucleic acid extraction and RT-PCR into a single, seamless workflow, enabling the detection of up to 20 targets from a single sample with exceptional precision and efficiency. The Rapi-Q series is engineered for fast, sensitive, and multiplex testing with a larger throughput, empowering healthcare providers with timely diagnostic insights that support improved patient outcomes. In genomics, Genes2Me offers one of the industry’s most comprehensive NGS clinical assay portfolios, spanning oncology, liquid biopsy, whole exome sequencing, NIPT and pharmacogenomics. Complementing this portfolio is EZY AutoPrep, our advanced automated library preparation workstation designed to optimize NGS library preparation through enhanced accuracy, reproducibility, and scalability. Our genomics ecosystem is further strengthened by CliSeq Interpreter, a cloud-based bioinformatics platform that enables accurate, flexible, and intuitive interpretation of complex genomic data, helping laboratories generate high-confidence insights with efficiency and ease. Driven by innovation, quality, and a global vision, Genes2Me continues to redefine the future of molecular diagnostics—delivering integrated solutions that advance precision medicine and improve lives worldwide.